Author

Robert P. Giugliano

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Aug 2026

Cumulative Benefit With Evolocumab in Patients With No Prior Myocardial Infarction or Stroke in the VESALIUS-CV Study.

BACKGROUND Proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab reduced the risk of a first major adverse cardiovascular event (MACE) in patients at high cardiovascular risk with no prior myocardial infarction (MI) or stroke in the VESALIUS-CV (Effect of Evolocumab in Patients at High Cardiovascular...

José C. Nicolau, Sabina A. Murphy, Robert P. Giugliano et al. · Journal of the American Coll... · 1 citation

Open access Aug 2026

Effects of Evolocumab on Mortality Outcomes in Patients Without Previous Myocardial Infarction or Stroke: A Prespecified Analysis of the VESALIUS-CV Randomized Clinical Trial.

BACKGROUND Evolocumab, a PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitor, significantly reduced the risk of cardiovascular events in patients without previous myocardial infarction or stroke in the VESALIUS-CV trial (Effect of Evolocumab in Patients at High Cardiovascular Risk without Prior Myocardial I...

Robert P. Giugliano, E. Bohula, A. Bellavia et al. · Circulation · 0 citations

Aug 2026

Efficacy and safety of olezarsen in patients with vs without baseline fibrate use.

Olezarsen reduced triglycerides across the hypertriglyceridemia spectrum, with greater effects in patients on background fibrates, particularly with diabetes, to support potential complementary mechanisms and further investigation of concomitant triglyceride-reducing therapy.

Annabel Z. Wang, V. Alexander, T. Prohaska et al. · Journal of Clinical Lipidolo... · 1 citation